iShares MSCI China ETF vs Stryker Corporation — how do they compare? iShares MSCI China ETF trades at $54.09, while Stryker Corporation trades at $315.68 (market cap $122.35B). The key difference: Stryker Corporation pays a 1% dividend while iShares MSCI China ETF pays none. Which is the better fit depends on your goals.
| MCHI | SYK | |
|---|---|---|
Sector | Broad Market / Factor | Technology |
52-Week High | $66.99 | $403.53 |
52-Week Low | $50.48 | $282.58 |
Market Cap | — | $122.35B |
Enterprise Value | — | $134.10B |
Dividend Yield | — | 1% |
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
Stryker (SYK) trades at $319.14, down 0.23% on the day, with a bearish technical signal despite strong fundamentals. The company reported $25.12B revenue and $3.25B net income for 2025, maintaining robust profitability with 63.83% gross margins and 13.21% net margins. Recent Q1 2026 earnings missed expectations due to a cybersecurity disruption, but management maintained full-year guidance. Analyst consensus remains strongly bullish with a $388.44 price target and 74% buy ratings.
The stock presents a compelling opportunity for long-term investors given its strong fundamentals and innovation pipeline, though near-term technical weakness and competitive pressures warrant caution. Upside potential exists from continued Mako robotics adoption and market share gains, while risks include cybersecurity vulnerabilities and integration challenges from acquisitions.
Trailing returns across standard periods
MCHI is an ETF that seeks to track the investment results of the MSCI China Index. It provides broad exposure to the Chinese equity market, primarily focusing on large and mid-cap companies listed in Hong Kong and Shanghai. MCHI serves as a core holding for investors looking to gain diversified exposure to the performance and growth potential of the companies within the People's Republic of China.
Read more on MCHI →Stryker is a global leader in medical technology, specializing in Orthopaedics, MedSurg, and Neurotechnology. It is renowned for its highly decentralized business model, which empowers 22 specialized business units to drive innovation and category leadership. With its market-leading Mako SmartRobotics™ platform and a relentless M&A strategy, Stryker provides a comprehensive ecosystem of connected surgical tools, implants, and digital solutions that improve both clinical and financial outcomes for hospitals worldwide.
Read more on SYK →